When the Well Runs Dry

Agres, Ted
October 2011
Drug Discovery & Development;Oct2011, Vol. 14 Issue 10, p10
The article focuses on the bipartisan legislation requiring pharmaceutical manufacturers to provide advance notice to the Food and Drug Administration (FDA) regarding potential shortages in the U.S. It notes that the Preserving Access to Life-Saving Medications Act also allows fines up to 10,000 dollars per day covering small chemical and biological drugs. Factors contributing to the shortages including microbial contamination, manufacturing problems, and exceeding market demand are also cited.


Related Articles

  • FDA Drug Approval to Change its Ways?  // Travel Medicine Advisor;May2008, Vol. 18 Issue 5, p1 

    The article deals with the issue on whether the drug approval process implemented by the U.S. Food and Drug Administration (FDA) should be changed. It is cited that the Prescription Drug Use Fee Act (PDUFA) enacted in 1992, which transformed the drug approval process of the FDA, is under...

  • Implementing Process Validation Guidances. Calcott, Peter H. // Contract Pharma;Mar2013, Vol. 15 Issue 2, p54 

    The article discusses how to implement the Process Validation Guidances which was released by the Food and Drug Administration for the pharmaceutical industry in the U.S. It mentions that the rationale and reasoning for process validation is described in the guidance. It describes three...

  • Blocking Biosimilars. Agres, Ted // Drug Discovery & Development;May/Jun2013, Vol. 16 Issue 3, p6 

    The article reports that drug manufacturers in the U.S. are trying to influence the decision of state legislatures to enact laws that will limit the substitution of biogenerics for brand name drugs. It states that the U.S. Food and Drug Administration (FDA) is trying to establish regulations for...

  • Pressure Mounts to Mend Holes in PDUFA Package. Serebrov, Mari // BioWorld Today;6/14/2012, Vol. 23 Issue 115, p1 

    The article reports on the mounting pressure for a U.S. congressional committee to address some issues on the Senate and House versions of the Prescription Drug User Fee Act (PDUFA) package. It focuses on the PDUFA's lack of an effective track-and-trace system for reinforcing the drug supply...

  • Looking for the Treatment for Drug Shortages: Not a Simple Prescription. Berry, Arnold J. // Mayo Clinic Proceedings;Mar2014, Vol. 89 Issue 3, p281 

    The article discusses research being done on drug shortages in the U.S. It references the study "Drug Shortages: A Complex Healthcare Crisis," by E. R. Fox, B. V. Sweet and V. Jensen published in the 2014 issue of "Mayo Clinic Proceedings." The researchers evaluated the passage of the FDA Safety...

  • More calls for action on drug shortages at Senate hearing.  // AHA News;12/19/2011, Vol. 47 Issue 25, p7 

    The article reports that American Society of Health-System Pharmacists' (ASHP) vice president of policy, planning and communications Kasey Thompson has declared that passage of the Preserving Access to Life Saving Medications Act, S.296/H.R. 2245 would help improve drug supply. The American...

  • WHERE DO WE GO NOW? THE HATCH-WAXMAN ACT TWENTY-FIVE YEARS LATER: SUCCESSES, FAILURES, AND PRESCRIPTIONS FOR THE FUTURE. Nussbaum, Linda P.; Radice, John D. // Rutgers Law Journal;Oct2009, Vol. 41 Issue 1/2, p229 

    The article focuses on the U.S. Hatch-Waxman Act and offers an overview of the regulatory history of pharmaceuticals in the U.S., including the formation of the Food and Drug Administration (FDA) in 1906. Information is provided on how the Hatch-Waxman Act allowed for the entry of generic drugs...

  • FDA and Justice Department Address Drug Quality Concerns. Wechsler, Jill // BioPharm International;Feb2012, Vol. 25 Issue 2, p11 

    The article reports on the billions of dollars recovered by the U.S. Department of Justice (DOJ) from the pharmaceutical industry for violations of Food and Drug Administration (FDA) rules and other federal laws in 2011. The violations include illegal marketing, pricing allegations and failure...

  • Colleagues, Where Is the Market Failure? Economists on the FDA. KLEIN, DANIEL B. // Econ Journal Watch;Sep2008, Vol. 5 Issue 3, p316 

    The article describes the absence of a market-failure rationale for the U.S. Food and Drug Administration (FDA) interventions and explores the writings of FDA-expressive economists and their political sociology. It cites FDA-administered restrictions including manufacturer speech control, permit...


Read the Article

Other Topics